Perspective · 2 Dec 2024
Conference abstract
Gaps in analytical methods registered by pharmaceutical labs
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
First of all, it???s important to talk about the current regulation where we are. We are in the Europe Union, where the Regulatory Authorities of each country is responsible of the approval of the marketing authorization of drugs and medical devices except the cases of centralized procedure (innovative products). These approvals are accepted by the member countries of the European Union once they are approved by European Medicines Agency (EMA). The main issues founded come from analytical methods approved by mutual recognition procedures. During the author???s professional experience he has observed many different gaps in the approved analytical methods. In his opinion there could be several factors involving the following: evaluators poorly trained in the evaluation of analytical methods, the ability of the pharmaceutical industry to get the approval of methods that don???t comply with the pharmacopoeia requirements, lack of data integrity in data management. The purpose of this conference is to talk about the gaps founded, how they can modify the analytical results and the responsibilities of each department involved in the validation of the analytical methods. The author is going to talk about concrete cases without mentioning specific laboratories but showing the weaknesses of their way of work. Some of the gaps he refers to are: dissolution methods with stirring speed of 200 rpm; use of non-standardized sinkers (ph Eur proposition); hiding chromatographic parameters; non-traceable chromatograms and no system suitability established. To conclude, we don???t have to panic as most of the gaps founded are due to a lack of updates of the dossiers. This updates require an administrative process, such as variations, which means paying additional fees. Due to this, the pharmaceutical industry tries to widen the time to make these payments. This situation could be solved if the Regulatory Authorities control the dossiers updates in a more exhaustive way.
Keywords
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 23 Sep 2024
Analytical method development and validation for the simultaneous estimation of valsartan and hydrochlorothiazide in bulk and pharmaceutical dosage forms by using rp-hplc method
Article · 31 Aug 2024
Analytical Method Development and Validation of Evogliptin in Pharmaceutical Dosage form by Ultraviolet Spectrophotometric Method
Review article · 29 Apr 2024
Analytical Method Development and Validation for the Simultaneous Estimation of Bempedoic Acid and Ezetimibe in Pure and Pharmaceutical Dosage Form- An Overview
Research article · 28 Sep 2023
Implementation of Quality by Design Approach to Analytical Method Development and Validation for Estimation of Morniflumate Pharmaceutical Dosage Form
More from this journal
The newest in Pharmaceutica Analytica Acta.
Article · 16 Sep 2026
The Fc Domains in the Monoclonal Antibody and Fusion Protein Significantly Boost the Biocomposite Suspension's Power to Combat Harmful Microorganisms, Enhance Drug Delivery, and Improve Protein Stability
Article · 26 Jun 2026
Green Pathways in Drug Quality Assessment: The Growing Role of Sustainable Pharmaceutical Analytics
Article · 26 Jun 2026
Advanced Single-Cell Signal Analysis: The Role of Ghost Cytometry in Cell Therapy Characterization
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutica Analytica Acta
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Joaquin Perea Leria”
- BylineArticles whose byline prints “Javier Garea Barriga”

